Inj inotuzumab ozogam 0.1 mg
Products billed under this code include Besponsa.
Payment limit per 0.1 MG, by effective quarter, 1Q21 to 4Q26. Gaps mean the code was not in that quarter’s file, or CMS gave no payment limit.Products billed under this code include Besponsa.
Payment limit per 0.1 MG, by effective quarter, 1Q21 to 4Q26. Gaps mean the code was not in that quarter’s file, or CMS gave no payment limit.From the 4Q26 NDC–HCPCS crosswalk. “Limit / pkg” is the 4Q26 payment limit times the billing units in one package.
| Product | Labeler | NDC | Units / pkg | Limit / pkg |
|---|---|---|---|---|
| Besponsa | Pfizer Inc | 00008-0100-01 | 9 | $25,857.927 |
| Quarter | Payment limit | Change | Billing unit | Description | Source file |
|---|---|---|---|---|---|
| 4Q26 | $2,873.103 | $0.00 | 0.1 MG | Inj inotuzumab ozogam 0.1 mg | v1, posted September 17, 2026 |
| 3Q26 | $2,873.103 | +$56.336 | 0.1 MG | Inj inotuzumab ozogam 0.1 mg | v1, posted September 15, 2026 |
| 2Q26 | $2,816.767 | $0.00 | 0.1 MG | Inj inotuzumab ozogam 0.1 mg | v1, posted September 15, 2026 |
| 1Q26 | $2,816.767 | +$118.714 | 0.1 MG | Inj inotuzumab ozogam 0.1 mg | v1, posted September 15, 2026 |
| 4Q25 | $2,698.053 | $0.00 | 0.1 MG | Inj inotuzumab ozogam 0.1 mg | v1, posted September 8, 2026 |
| 3Q25 | $2,698.053 | +$39.924 | 0.1 MG | Inj inotuzumab ozogam 0.1 mg | v1, posted March 10, 2026 |
| 2Q25 | $2,658.129 | $0.00 | 0.1 MG | Inj inotuzumab ozogam 0.1 mg | v1, posted March 10, 2026 |
| 1Q25 | $2,658.129 | +$39.282 | 0.1 MG | Inj inotuzumab ozogam 0.1 mg | v1, posted December 19, 2025 |
| 4Q24 | $2,618.847 | $0.00 | 0.1 MG | Inj inotuzumab ozogam 0.1 mg | v1, posted June 11, 2025 |
| 3Q24 | $2,618.847 | +$38.702 | 0.1 MG | Inj inotuzumab ozogam 0.1 mg | v1, posted June 11, 2025 |
| 2Q24 | $2,580.145 | $0.00 | 0.1 MG | Inj inotuzumab ozogam 0.1 mg | v1, posted March 11, 2025 |
| 1Q24 | $2,580.145 | +$50.592 | 0.1 MG | Inj inotuzumab ozogam 0.1 mg | v1, posted December 19, 2024 |
| 4Q23 | $2,529.553 | $0.00 | 0.1 MG | Inj inotuzumab ozogam 0.1 mg | v1, posted October 10, 2024 |
| 3Q23 | $2,529.553 | +$49.598 | 0.1 MG | Inj inotuzumab ozogam 0.1 mg | v1, posted June 5, 2024 |
| 2Q23 | $2,479.955 | +$2.331 | 0.1 MG | Inj inotuzumab ozogam 0.1 mg | v1, posted February 23, 2024 |
| 1Q23 | $2,477.624 | +$34.319 | 0.1 MG | Inj inotuzumab ozogam 0.1 mg | v1, posted December 6, 2023 |
| 4Q22 | $2,443.305 | $0.00 | 0.1 MG | Inj inotuzumab ozogam 0.1 mg | v1, posted June 22, 2023 |
| 3Q22 | $2,443.305 | +$36.109 | 0.1 MG | Inj inotuzumab ozogam 0.1 mg | v1, posted June 9, 2023 |
| 2Q22 | $2,407.196 | $0.00 | 0.1 MG | Inj inotuzumab ozogam 0.1 mg | v1, posted December 14, 2022 |
| 1Q22 | $2,407.196 | +$35.574 | 0.1 MG | Inj inotuzumab ozogam 0.1 mg | v1, posted June 8, 2022 |
| 4Q21 | $2,371.622 | $0.00 | 0.1 MG | Inj inotuzumab ozogam 0.1 mg | v1, posted June 2, 2022 |
| 3Q21 | $2,371.622 | +$30.528 | 0.1 MG | Inj inotuzumab ozogam 0.1 mg | v1, posted June 2, 2022 |
| 2Q21 | $2,341.094 | −$0.203 | 0.1 MG | Inj inotuzumab ozogam 0.1 mg | v1, posted March 1, 2022 |
| 1Q21 | $2,341.297 | – | 0.1 MG | Inj inotuzumab ozogam 0.1 mg | v1, posted December 10, 2021 |
“Change” is the difference from the previous quarter, shown only when both quarters have a payment limit and the billing unit is the same. “vs. last quarter” and “vs. a year ago” follow the same rule.